Zumutor Biologics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Zumutor Biologics is a biotechnology research company developing novel immuno-oncology therapeutics that aim to enhance cancer treatment through NK cell engagement. The company leverages INABLR, its proprietary antibody discovery platform, to accelerate antibody discovery and development and works with a scientific advisory board specializing in immuno-oncology and clinical development.

Its lead asset, ZM008, is a first-in-class monoclonal antibody that targets tumor cell receptors to block NK cell inhibitory signals and promote NK cell–mediated immune responses. In 2023, ZM008 advanced through regulatory milestones, including FDA clearance to initiate clinical trials and later its public launch. The company is headquartered in Cambridge, Massachusetts, with research and development conducted in an ISO-certified laboratory in Bangalore, India.

Sign up for free to view info

Company overview Employee directory